The Build – Ansa Biotechnologies
Ansa CEO Jason T. Gammack speaks with Chenny Zhang of Cerberus Ventures about how the company is empowering critical research and scientific breakthroughs with it’s innovative enzymatic DNA synthesis technology.
Ansa’s On-Time Guarantee
If Your DNA Ships Late, It’s Free
Delays in DNA synthesis can derail research and project timelines. In this video, Ansa CEO Jason T. Gammack explains the Ansa On-Time Guarantee and why it matters for biotech, pharma, and research teams that rely on fast, reliable synthetic DNA. Ansa is the only synthetic DNA provider offering a simple guarantee: if your DNA order doesn’t ship on time, it’s free. Learn how this on-time shipping guarantee helps teams avoid costly delays and stay on schedule.
Company Videos
A Unique Enzymatic DNA Synthesis Technology
Ansa’s innovative enzymatic DNA synthesis technology offers key benefits over other DNA synthesis methods — chemical and enzymatic. Watch the video to learn more.
Reshaping Biology
Explore how Ansa’s groundbreaking DNA synthesis technology empowers scientists to achieve the next wave of scientific breakthroughs and shape the future of biology.
The Road to Commercialization
Humbling Moments in a Startup
Everyone trips a little on their road to success, and we’re no different. In the second installment of our new video series, our co-founders share some amusing look-backs.
What’s in a Name?
Our company name is often mispronounced. In this video, our CSO Dan Lin-Arlow clarifies and shares the backstory of how it came to be.
The Scientists’ Perspective
The Truth About Codon Optimization
During a panel discussion SynBioBeta 2024, Tae Seok Moon, PhD, from the J. Craig Venter Institute, imagines the future of biology and addresses the truth about codon optimization.
Tackling Mycobacteria Phages
New England Biolabs molecular biologist, Greg Lohman, PhD, talks about how working with Ansa has enabled his team to build fully synthetic systems that were not possible before.
Complexity Delivered
Jaymin Patel, PhD, from the Cress Lab at The Innovative Genomics Institute, shares how Ansa has been able to deliver complex sequences that other vendors have rejected, further enabling his work.